Internet-Based Versus Face-to-Face Cognitive-Behavioral Therapy for Social Anxiety Disorder: A Randomized Control Trial
Behav Ther. 2024 May;55(3):528-542. doi: 10.1016/j.beth.2023.08.005. Epub 2023 Sep 4.ABSTRACTDuring the COVID-19 epidemic, face-to-face mental health services faced obstacles. Using Internet-based interventions was a good solution and had the potential to overcome these treatment barriers. However, there is no strong research evidence about the effectiveness of these methods for social anxiety disorder in different cultures and developing countries. Therefore, the present study aimed to investigate the effectiveness and application of Internet-based cognitive-behavioral therapy for social anxiety disorder in Iran. The curr...
Source: Behavior Therapy - April 26, 2024 Category: Psychiatry & Psychology Authors: Hassan Soleimani Rad Hanieh Goodarzi Leili Bahrami Abbas Abolghasemi Source Type: research
Self-compassion, Positive and Negative Affect and Social Avoidance among Adolescence: Mediating Role of Mindfulness
CONCLUSION: Mindfulness is the awareness and acceptance of the feelings, thoughts and sensations attached to self and its possible reciprocity with social surroundings to mitigate fear-self-compassion and positive emotional affect augment, and negative emotional affect attenuate mindfulness. Results analysis highlights the mediation of mindfulness on social anxiety, self-compassion, positive affect, and negative affect.PMID:38660066 | PMC:PMC11041389 | DOI:10.2174/0117450179268979231114045116 (Source: Clinical Practice and Epidemiology in Mental Health)
Source: Clinical Practice and Epidemiology in Mental Health - April 25, 2024 Category: Psychiatry Authors: M S Sujamani Barani Kanth Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
Self-compassion, Positive and Negative Affect and Social Avoidance among Adolescence: Mediating Role of Mindfulness
CONCLUSION: Mindfulness is the awareness and acceptance of the feelings, thoughts and sensations attached to self and its possible reciprocity with social surroundings to mitigate fear-self-compassion and positive emotional affect augment, and negative emotional affect attenuate mindfulness. Results analysis highlights the mediation of mindfulness on social anxiety, self-compassion, positive affect, and negative affect.PMID:38660066 | PMC:PMC11041389 | DOI:10.2174/0117450179268979231114045116 (Source: Clinical Practice and Epidemiology in Mental Health)
Source: Clinical Practice and Epidemiology in Mental Health - April 25, 2024 Category: Psychiatry Authors: M S Sujamani Barani Kanth Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
Self-compassion, Positive and Negative Affect and Social Avoidance among Adolescence: Mediating Role of Mindfulness
CONCLUSION: Mindfulness is the awareness and acceptance of the feelings, thoughts and sensations attached to self and its possible reciprocity with social surroundings to mitigate fear-self-compassion and positive emotional affect augment, and negative emotional affect attenuate mindfulness. Results analysis highlights the mediation of mindfulness on social anxiety, self-compassion, positive affect, and negative affect.PMID:38660066 | PMC:PMC11041389 | DOI:10.2174/0117450179268979231114045116 (Source: Clinical Practice and Epidemiology in Mental Health)
Source: Clinical Practice and Epidemiology in Mental Health - April 25, 2024 Category: Psychiatry Authors: M S Sujamani Barani Kanth Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
